831 AXL Receptor Tyrosine Kinase Expression in Metastatic Renal Cell Carcinoma: Insights from the METEOR trial
Yasmin Nabil Laimon(Brigham and Women's Hospital), Sabina Signoretti(Brigham and Women's Hospital), David Braun(Yale University), Sayed Matar(Brigham and Women's Hospital), Toni K. Choueiri(Harvard University), Nourhan El Ahmar(Brigham and Women's Hospital), Wanling Xie(Dana-Farber Cancer Institute), Marc Machaalani(Dana-Farber Cancer Institute), Dana T. Aftab(Exelixis (United States)), Tejas Jammihal(Children's Hospital of Philadelphia), Sachet A. Shukla(The University of Texas MD Anderson Cancer Center), Razan Mohanna(Brigham and Women's Hospital), Paul Morgan(University of Pittsburgh), Maxine Sun(Dana-Farber Cancer Institute), Fatme Ghandour(University of Alabama at Birmingham), Berkay Simsek(Brigham and Women's Hospital), Eddy Saad(Dana-Farber Cancer Institute), Andrew Delcea(Brigham and Women's Hospital), Thomas Denize(Harvard University)
Cited by 2
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
|Cell|2015|4.2k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k